National Toxicology Program

National Toxicology Program
https://ntp.niehs.nih.gov/go/905

TDMS Study 05109-14 Pathology Tables

NTP Experiment-Test: 05109-14  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                          TRIETHANOLAMINE                                      Date: 01/14/03
Route: SKIN APPLICATION                                                                                           Time: 14:27:26




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  102-71-6

       Lock Date:  05/31/01

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All




































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 05109-14  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                          TRIETHANOLAMINE                                      Date: 01/14/03  
Route: SKIN APPLICATION                                                                                           Time: 14:27:26  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 MG/KG      100          300          1000                                      
                                                                MG/KG        MG/KG        MG/KG                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          50           50           50           50                                     
  Early Deaths                                                                                                                      
    Natural Death                                      7            6            4            7                                     
    Moribund Sacrifice                                 8           10            5           10                                     
    Accidently Killed                                                                         1                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                34           34           41           32                                     
    Natural Death                                      1                                                                            
                                                                                                                                    
  Animals Examined Microscopically                    50           50           50           50                                     
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Large, Colon                             (50)         (50)         (50)         (50)                                   
      Leiomyoma                                                                               1 (2%)                                
   Intestine Large, Rectum                            (50)         (50)         (50)         (50)                                   
      Leiomyosarcoma, Metastatic, Uterus                                                      1 (2%)                                
   Intestine Large, Cecum                             (50)         (50)         (50)         (50)                                   
   Intestine Small, Jejunum                           (50)         (50)         (50)         (50)                                   
      Carcinoma                                                     1 (2%)                                                          
      Polyp Adenomatous                                                          1 (2%)                                             
   Liver                                              (50)         (50)         (50)         (50)                                   
      Hemangioma                                       1 (2%)                                                                       
      Hemangiosarcoma                                               1 (2%)                                                          
      Hepatocellular Carcinoma                         5 (10%)      8 (16%)      4 (8%)       5 (10%)                               
      Hepatocellular Carcinoma, Multiple               1 (2%)                                                                       
      Hepatocellular Adenoma                           9 (18%)     15 (30%)     13 (26%)     16 (32%)                               
      Hepatocellular Adenoma, Multiple                              3 (6%)       7 (14%)     17 (34%)                               
      Histiocytic Sarcoma                              4 (8%)       5 (10%)                   3 (6%)                                
   Mesentery                                          (11)         (6)          (4)          (9)                                    
      Liposarcoma                                                                1 (25%)                                            
   Oral Mucosa                                        (26)         (26)         (31)         (31)                                   
      Histiocytic Sarcoma                              1 (4%)                                                                       
   Pancreas                                           (50)         (50)         (50)         (50)                                   
      Histiocytic Sarcoma                                           1 (2%)                                                          
   Salivary Glands                                    (50)         (50)         (50)         (50)                                   
      Carcinoma                                                                               1 (2%)                                
   Stomach, Forestomach                               (50)         (50)         (50)         (50)                                   
      Squamous Cell Papilloma                          2 (4%)                    2 (4%)       4 (8%)                                
      Squamous Cell Papilloma, Multiple                                          1 (2%)                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 05109-14  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                          TRIETHANOLAMINE                                      Date: 01/14/03  
Route: SKIN APPLICATION                                                                                           Time: 14:27:26  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 MG/KG      100          300          1000                                      
                                                                MG/KG        MG/KG        MG/KG                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - cont                                                                                                            
   Stomach, Glandular                                 (50)         (50)         (50)         (50)                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (50)         (50)         (50)         (50)                                   
      Hemangiosarcoma                                  1 (2%)                                                                       
      Histiocytic Sarcoma                              1 (2%)       2 (4%)                    1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (50)         (50)         (50)         (50)                                   
      Carcinoma                                                     1 (2%)                                                          
      Histiocytic Sarcoma                                           1 (2%)                                                          
      Subcapsular, Adenoma                                                                    1 (2%)                                
   Adrenal Medulla                                    (49)         (50)         (50)         (50)                                   
      Pheochromocytoma Benign                          1 (2%)                    1 (2%)                                             
   Islets, Pancreatic                                 (50)         (50)         (50)         (50)                                   
      Adenoma                                                       1 (2%)       1 (2%)       1 (2%)                                
   Pituitary Gland                                    (50)         (50)         (50)         (50)                                   
      Pars Distalis, Adenoma                           8 (16%)      5 (10%)      5 (10%)      5 (10%)                               
      Pars Distalis, Carcinoma                                                                1 (2%)                                
      Pars Intermedia, Adenoma                                      3 (6%)       1 (2%)                                             
   Thyroid Gland                                      (50)         (50)         (50)         (50)                                   
      Follicle, Adenoma                                                          1 (2%)       3 (6%)                                
      Follicle, Carcinoma                              1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (50)         (50)         (50)         (50)                                   
      Cystadenoma                                      1 (2%)       1 (2%)                    1 (2%)                                
      Granulosa Cell Tumor Malignant                                                          1 (2%)                                
      Histiocytic Sarcoma                              2 (4%)       2 (4%)                    1 (2%)                                
      Luteoma                                          1 (2%)       1 (2%)                                                          
      Teratoma Benign                                                                         1 (2%)                                
      Tubulostromal Adenoma                                                                   1 (2%)                                
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 05109-14  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                          TRIETHANOLAMINE                                      Date: 01/14/03  
Route: SKIN APPLICATION                                                                                           Time: 14:27:26  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 MG/KG      100          300          1000                                      
                                                                MG/KG        MG/KG        MG/KG                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
GENITAL SYSTEM - cont                                                                                                               
   Uterus                                             (50)         (50)         (50)         (50)                                   
      Histiocytic Sarcoma                              3 (6%)       3 (6%)                    1 (2%)                                
      Leiomyosarcoma                                                1 (2%)                    2 (4%)                                
      Polyp Stromal                                    1 (2%)                    3 (6%)       1 (2%)                                
   Vagina                                                                                    (1)                                    
      Leiomyosarcoma, Metastatic, Uterus                                                      1 (100%)                              
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (50)         (50)         (50)         (50)                                   
      Histiocytic Sarcoma                              1 (2%)       1 (2%)                    1 (2%)                                
   Lymph Node                                         (6)          (7)          (4)          (6)                                    
      Iliac, Histiocytic Sarcoma                                    1 (14%)                                                         
      Lumbar, Histiocytic Sarcoma                      1 (17%)                                                                      
      Mediastinal, Liposarcoma, Metastatic,                                                                                         
        Mesentery                                                                1 (25%)                                            
      Renal, Histiocytic Sarcoma                                    1 (14%)                                                         
   Lymph Node, Mandibular                             (49)         (50)         (50)         (50)                                   
      Histiocytic Sarcoma                                           1 (2%)                                                          
   Lymph Node, Mesenteric                             (50)         (49)         (48)         (48)                                   
      Histiocytic Sarcoma                                           3 (6%)                                                          
   Spleen                                             (50)         (50)         (49)         (50)                                   
      Hemangiosarcoma                                  1 (2%)                    1 (2%)       1 (2%)                                
      Histiocytic Sarcoma                              2 (4%)       3 (6%)                                                          
   Thymus                                             (49)         (49)         (49)         (49)                                   
      Histiocytic Sarcoma                                           1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (50)         (50)         (50)         (50)                                   
      Sebaceous Gland, Adenoma                         1 (2%)                                                                       
      Subcutaneous Tissue, Fibrosarcoma                1 (2%)       1 (2%)       2 (4%)       1 (2%)                                
      Subcutaneous Tissue, Hemangiosarcoma                                                    1 (2%)                                
      Subcutaneous Tissue, Hemangiosarcoma,                                                                                         
        Multiple                                       1 (2%)                                                                       
      Subcutaneous Tissue, Histiocytic Sarcoma         1 (2%)                                 1 (2%)                                
      Subcutaneous Tissue, Melanoma Malignant,                                                                                      
         Multiple                                      1 (2%)                                                                       
      Subcutaneous Tissue, Osteosarcoma                1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 05109-14  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                          TRIETHANOLAMINE                                      Date: 01/14/03  
Route: SKIN APPLICATION                                                                                           Time: 14:27:26  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 MG/KG      100          300          1000                                      
                                                                MG/KG        MG/KG        MG/KG                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (50)         (50)         (50)         (50)                                   
      Osteosarcoma                                                  1 (2%)                                                          
   Skeletal Muscle                                    (1)          (2)          (1)          (3)                                    
      Hemangiosarcoma, Metastatic, Spleen                                        1 (100%)                                           
      Rhabdomyosarcoma                                 1 (100%)     2 (100%)                  2 (67%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (50)         (50)         (49)         (50)                                   
      Histiocytic Sarcoma                              1 (2%)                                 1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)         (50)         (50)         (50)                                   
      Alveolar/Bronchiolar Adenoma                     3 (6%)       1 (2%)       2 (4%)       1 (2%)                                
      Alveolar/Bronchiolar Carcinoma                   2 (4%)       2 (4%)       3 (6%)       1 (2%)                                
      Carcinoma, Metastatic, Harderian Gland           1 (2%)                                                                       
      Hemangiosarcoma, Metastatic, Heart               1 (2%)                                                                       
      Hepatocellular Carcinoma, Metastatic, Liver      3 (6%)       3 (6%)                    2 (4%)                                
      Histiocytic Sarcoma                              4 (8%)       4 (8%)                    1 (2%)                                
      Liposarcoma, Metastatic, Mesentery                                         1 (2%)                                             
      Osteosarcoma, Metastatic, Bone                                1 (2%)                                                          
      Osteosarcoma, Metastatic, Skin                   1 (2%)                                                                       
   Nose                                               (50)         (50)         (50)         (50)                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Eye                                                (49)         (50)         (50)         (50)                                   
   Harderian Gland                                    (49)         (50)         (50)         (50)                                   
      Adenoma                                          5 (10%)      5 (10%)      3 (6%)       3 (6%)                                
      Carcinoma                                        2 (4%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (50)         (50)         (50)         (50)                                   
      Histiocytic Sarcoma                              2 (4%)       3 (6%)                                                          
      Renal Tubule, Adenoma                                                                   1 (2%)                                
   Urinary Bladder                                    (50)         (50)         (49)         (49)                                   
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 05109-14  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                          TRIETHANOLAMINE                                      Date: 01/14/03  
Route: SKIN APPLICATION                                                                                           Time: 14:27:26  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 MG/KG      100          300          1000                                      
                                                                MG/KG        MG/KG        MG/KG                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(50)        *(50)        *(50)        *(50)                                   
      Histiocytic Sarcoma                              4 (8%)       5 (10%)                   3 (6%)                                
      Lymphoma Malignant                               8 (16%)      9 (18%)      6 (12%)      8 (16%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 05109-14  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                          TRIETHANOLAMINE                                      Date: 01/14/03  
Route: SKIN APPLICATION                                                                                           Time: 14:27:26  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 MG/KG      100          300          1000                                      
                                                                MG/KG        MG/KG        MG/KG                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            38          41          35          44                                       
     Total Primary Neoplasms                           63          67          58          84                                       
                                                                                                                                    
   Total Animals with Benign Neoplasms                 24          28          27          38                                       
     Total Benign Neoplasms                            33          35          41          57                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms              27          26          16          21                                       
     Total Malignant Neoplasms                         30          32          17          27                                       
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              6           4           2           3                                       
     Total Metastatic Neoplasm                          6           4           3           4                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 05109-14  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                          TRIETHANOLAMINE                                      Date: 01/14/03  
Route: SKIN APPLICATION                                                                                           Time: 14:27:26  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      200          630          2000                                      
                                                                MG/KG        MG/KG        MG/KG                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          50           50           50           50                                     
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 5            2            6            8                                     
    Natural Death                                      8            5           10            2                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                37           43           34           40                                     
                                                                                                                                    
  Animals Examined Microscopically                    50           50           50           50                                     
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Small, Jejunum                           (50)         (50)         (50)         (50)                                   
      Adenoma                                                                                 1 (2%)                                
      Carcinoma                                        2 (4%)       1 (2%)                    1 (2%)                                
      Carcinoma, Multiple                              1 (2%)                                                                       
      Sarcoma, Metastatic, Adrenal Medulla                          1 (2%)                                                          
   Liver                                              (50)         (50)         (50)         (50)                                   
      Hemangioma                                                    1 (2%)                    2 (4%)                                
      Hemangiosarcoma                                  1 (2%)                    4 (8%)       1 (2%)                                
      Hemangiosarcoma, Multiple                                                  2 (4%)                                             
      Hemangiosarcoma, Metastatic, Blood Vessel                                               1 (2%)                                
      Hemangiosarcoma, Metastatic, Spleen              1 (2%)       1 (2%)       1 (2%)                                             
      Hepatoblastoma                                   1 (2%)       1 (2%)       2 (4%)       3 (6%)                                
      Hepatocellular Carcinoma                        11 (22%)     10 (20%)     13 (26%)     10 (20%)                               
      Hepatocellular Carcinoma, Multiple               6 (12%)      4 (8%)       1 (2%)       1 (2%)                                
      Hepatocellular Adenoma                          13 (26%)     14 (28%)     12 (24%)     15 (30%)                               
      Hepatocellular Adenoma, Multiple                 6 (12%)      4 (8%)      11 (22%)      5 (10%)                               
      Hepatocholangiocarcinoma                                                                1 (2%)                                
      Histiocytic Sarcoma                                           1 (2%)                    2 (4%)                                
      Sarcoma, Metastatic, Adrenal Medulla                          1 (2%)                                                          
   Mesentery                                          (3)          (3)          (5)          (7)                                    
      Fibrous Histiocytoma                                                                    1 (14%)                               
   Stomach, Forestomach                               (50)         (50)         (50)         (50)                                   
      Squamous Cell Papilloma                          1 (2%)       2 (4%)                    1 (2%)                                
   Tongue                                                                                    (1)                                    
      Squamous Cell Carcinoma                                                                 1 (100%)                              
   Tooth                                              (19)         (18)         (14)         (13)                                   
      Odontoma                                         1 (5%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 05109-14  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                          TRIETHANOLAMINE                                      Date: 01/14/03  
Route: SKIN APPLICATION                                                                                           Time: 14:27:26  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      200          630          2000                                      
                                                                MG/KG        MG/KG        MG/KG                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Blood Vessel                                       (50)         (50)         (50)         (50)                                   
      Aorta, Hemangiosarcoma                                                                  1 (2%)                                
   Heart                                              (50)         (50)         (50)         (50)                                   
      Carcinoma, Metastatic, Kidney                                                           1 (2%)                                
      Fibrous Histiocytoma, Metastatic, Mesentery                                             1 (2%)                                
      Histiocytic Sarcoma                                                                     1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (50)         (50)         (50)         (50)                                   
      Alveolar/Bronchiolar Carcinoma, Metastatic,                                                                                   
         Lung                                                                    1 (2%)                                             
      Subcapsular, Adenoma                             3 (6%)       3 (6%)       6 (12%)      5 (10%)                               
   Adrenal Medulla                                    (50)         (50)         (50)         (50)                                   
      Pheochromocytoma Benign                          1 (2%)                                 1 (2%)                                
      Sarcoma                                                       1 (2%)                                                          
   Pituitary Gland                                    (50)         (49)         (49)         (50)                                   
      Pars Distalis, Adenoma                                                     1 (2%)                                             
      Pars Intermedia, Adenoma                         1 (2%)                                 1 (2%)                                
   Thyroid Gland                                      (50)         (50)         (49)         (50)                                   
      Follicle, Adenoma                                1 (2%)                    1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Epididymis                                         (50)         (50)         (50)         (50)                                   
      Fibrous Histiocytoma, Metastatic, Mesentery                                             1 (2%)                                
   Testes                                             (50)         (50)         (50)         (50)                                   
      Interstitial Cell, Adenoma                                    1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
NTP Experiment-Test: 05109-14  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                          TRIETHANOLAMINE                                      Date: 01/14/03  
Route: SKIN APPLICATION                                                                                           Time: 14:27:26  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      200          630          2000                                      
                                                                MG/KG        MG/KG        MG/KG                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (50)         (50)         (50)         (50)                                   
      Hemangiosarcoma, Metastatic, Spleen              1 (2%)                    1 (2%)                                             
      Histiocytic Sarcoma                                                                     1 (2%)                                
   Lymph Node                                         (1)                       (1)          (1)                                    
      Mediastinal, Alveolar/Bronchiolar Carcinoma,                                                                                  
         Metastatic, Lung                              1 (100%)                                                                     
      Mediastinal, Fibrous Histiocytoma,                                                                                            
        Metastatic, Mesentery                                                                 1 (100%)                              
      Mediastinal, Hepatocellular Carcinoma,                                                                                        
        Metastatic, Liver                                                        1 (100%)                                           
      Pancreatic, Fibrous Histiocytoma, Metastatic,                                                                                 
         Mesentery                                                                            1 (100%)                              
      Renal, Fibrous Histiocytoma                                                             1 (100%)                              
   Lymph Node, Mesenteric                             (50)         (48)         (48)         (50)                                   
      Histiocytic Sarcoma                                                                     1 (2%)                                
   Spleen                                             (49)         (50)         (50)         (50)                                   
      Hemangioma                                       1 (2%)                                                                       
      Hemangiosarcoma                                  2 (4%)       2 (4%)       2 (4%)                                             
      Histiocytic Sarcoma                                           1 (2%)                    1 (2%)                                
   Thymus                                             (48)         (47)         (48)         (48)                                   
      Alveolar/Bronchiolar Carcinoma, Metastatic,                                                                                   
         Lung                                                                    1 (2%)                                             
      Carcinoma, Metastatic, Kidney                                                           1 (2%)                                
      Fibrous Histiocytoma, Metastatic, Mesentery                                             1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (50)         (50)         (50)         (50)                                   
      Squamous Cell Carcinoma                                                                 1 (2%)                                
      Subcutaneous Tissue, Hibernoma                                                          1 (2%)                                
      Subcutaneous Tissue, Melanoma Malignant          1 (2%)                                                                       
      Subcutaneous Tissue, Skin, Site of                                                                                            
        Application, Hemangiosarcoma                                             1 (2%)                                             
      Subcutaneous Tissue, Site of Application -                                                                                    
        Dermis, Mast Cell Tumor Benign                              1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  10                                                               
                                                                                                                                   
NTP Experiment-Test: 05109-14  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                          TRIETHANOLAMINE                                      Date: 01/14/03  
Route: SKIN APPLICATION                                                                                           Time: 14:27:26  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      200          630          2000                                      
                                                                MG/KG        MG/KG        MG/KG                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (50)         (50)         (50)         (50)                                   
      Osteosarcoma                                     1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)         (50)         (50)         (50)                                   
      Alveolar/Bronchiolar Adenoma                     6 (12%)      6 (12%)     11 (22%)      7 (14%)                               
      Alveolar/Bronchiolar Adenoma, Multiple                        1 (2%)       1 (2%)       2 (4%)                                
      Alveolar/Bronchiolar Carcinoma                   6 (12%)      6 (12%)      8 (16%)      3 (6%)                                
      Alveolar/Bronchiolar Carcinoma, Multiple         1 (2%)                                 1 (2%)                                
      Carcinoma, Metastatic, Harderian Gland                        1 (2%)                                                          
      Carcinoma, Metastatic, Kidney                                                           1 (2%)                                
      Fibrous Histiocytoma, Metastatic, Mesentery                                             1 (2%)                                
      Hepatoblastoma, Metastatic, Liver                                          1 (2%)       1 (2%)                                
      Hepatocellular Carcinoma, Metastatic, Liver      8 (16%)      6 (12%)      6 (12%)      2 (4%)                                
      Hepatocholangiocarcinoma, Metastatic, Liver                                             1 (2%)                                
      Histiocytic Sarcoma                                           1 (2%)                    2 (4%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Harderian Gland                                    (50)         (50)         (49)         (50)                                   
      Adenoma                                          6 (12%)      2 (4%)       2 (4%)       5 (10%)                               
      Carcinoma                                                     1 (2%)                    1 (2%)                                
      Bilateral, Adenoma                               1 (2%)                                 1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (50)         (50)         (50)         (50)                                   
      Histiocytic Sarcoma                                           1 (2%)                    1 (2%)                                
      Renal Tubule, Adenoma                            1 (2%)                    1 (2%)       1 (2%)                                
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  11                                                               
                                                                                                                                   
NTP Experiment-Test: 05109-14  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                          TRIETHANOLAMINE                                      Date: 01/14/03  
Route: SKIN APPLICATION                                                                                           Time: 14:27:26  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      200          630          2000                                      
                                                                MG/KG        MG/KG        MG/KG                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
URINARY SYSTEM - cont                                                                                                               
      Renal Tubule, Carcinoma, Multiple                                                       1 (2%)                                
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(50)        *(50)        *(50)        *(50)                                   
      Histiocytic Sarcoma                                           1 (2%)                    2 (4%)                                
      Lymphoma Malignant                                                         1 (2%)       1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  12                                                               
                                                                                                                                   
NTP Experiment-Test: 05109-14  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                          TRIETHANOLAMINE                                      Date: 01/14/03  
Route: SKIN APPLICATION                                                                                           Time: 14:27:26  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      200          630          2000                                      
                                                                MG/KG        MG/KG        MG/KG                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            45          35          43          41                                       
     Total Primary Neoplasms                           75          62          80          79                                       
                                                                                                                                    
   Total Animals with Benign Neoplasms                 30          25          32          32                                       
     Total Benign Neoplasms                            42          35          46          48                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms              28          24          27          21                                       
     Total Malignant Neoplasms                         33          27          34          31                                       
                                                                                                                                    
   Total Animals with Metastatic Neoplasms             10           8           9           6                                       
     Total Metastatic Neoplasm                         11          10          12          14                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  13                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------                                           
NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.